期刊文献+

2001~2005年江苏省盐都区病毒性肝炎血清流行病学监测 被引量:8

Seroepidemiological surveillance of viral hepatitis in Yandu District from 2001 to 2005.
下载PDF
导出
摘要 目的研究一般人群血清病毒性肝炎免疫水平。方法在省级病毒性肝炎血清流行病学监测点内分别于2001、2003、2005年对一般人群免疫水平进行血清流行病学监测,用酶联免疫吸附法(ELISA)检测抗-HAV-IgG、HBsAg、抗-HBs、抗-HBc、抗-HCV等。结果抗-HAV-IgG总阳性检出率为82.38%,HBsAg总阳性检出率2.79%,抗-HBs总阳性检出率57.04%,抗-HBc总阳性检出率46.94%,抗-HCV总阳性检出率0.08%。结论一般人群甲型肝炎抗体较高,表明有关控制甲型肝炎的干预措施切实有效。乙型肝炎防治措施的重点应为,加强对10 ̄20岁年龄组的疫苗接种。 Objective The present study was conducted to get the knowledge of the serum immune level of general population against viral hepatitis. Methods Seroepidemiological surveillance was conducted on immune level of general population at provincial seroepidemiological surveiUance spots for viral hepatitis in 2001, 2003, 2005 respectively. ELISA was adopted to detect HAV-IgG antibody, HBs antigen, HBs antibody, HBc antibody, HCV antibody and so on. Results The total positive detection rates of HAV-IgG antibody, HBs antigen, HBs antibody, HBc antibody and HCV antibody were respectively 82.38%, 2.79%, 57.04%, 46.94% and 0.08%. Condusion In general population, the level of Type A Hepatitis antibody was relatively high, which showed that the intervention measures to control Type A Hepatitis was quite effective. And the key point of the prevention and control of Type B Hepatitis should be to strengthen vaccination in the group aged 10-20.
出处 《疾病监测》 CAS 2006年第11期577-579,584,共4页 Disease Surveillance
关键词 一般人群 病毒性肝炎 免疫水平 血清流行病学 监测 general population viral hepatitis immune level seroepidemiology surveillance
  • 相关文献

参考文献6

二级参考文献23

  • 1李良成,王容华,林和顺,余国彦,何天菲,陈巧惠,陈静文.深圳市病毒性肝炎人群感染状况监测[J].中国公共卫生,1994,10(12):563-565. 被引量:3
  • 2李荣成,杨进业,王树声,龚健,李艳萍,农艺,陈荣修,曹惠霖,刘崇柏,徐志一.乙型肝炎疫苗免疫接种对乙型肝炎病毒感染流行率的影响[J].中国计划免疫,1996,2(2):56-60. 被引量:37
  • 3朱荣 曹文英 李显.中国病毒性肝炎血清流行病学调查(下卷)·江苏省病毒性肝炎流行病学调查[M].北京:科学技术文献出版社,1999.63-68.
  • 4Tomans G, Van Damme P, Doorsaer E, et al. Cost-effectiveness analysis of hepatitis A prevention in travlers[J]. Vaccine, 1992,10(1 ) : 88-89.
  • 5Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol, 2003, 38(suppl 1)∶s1014-s1118.
  • 6Booth JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut, 2001, 49(suppl 1)∶ s1-s21.
  • 7Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002, 51∶864-869.
  • 8Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review. Hepatology,2002,36(5 suppl 1)∶s135-s144.
  • 9Di Ciommo V, Russo P, Rava L, et al. Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis. J Viral Hepat, 2003, 10∶210-214.
  • 10Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther, 2003, 18∶1071-1081.

共引文献141

同被引文献85

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部